KOREAN DRUG CO., LTD.
Financials
Valuation Metrics
KOREAN DRUG CO., LTD.'s Market Cap is ₩372B. At end of 2025 it was ₩473B. Ranked #1916 of 2,436 in KR market (top 79%), #1192 of 1,649 on KOSDAQ (top 72%), #208 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 89%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 37.18B KRW | KR#1,916/2,436 Sec#208/234 |
| Revenue | 62.76B KRW | KR#1,664/2,436 Sec#110/234 |
| Net Income | 6.91B KRW | KR#1,026/2,436 Sec#68/234 |
| Total Assets | 96.39B KRW | KR#1,768/2,436 Sec#143/234 |
| Net Assets | 82.31B KRW | KR#1,535/2,436 Sec#127/234 |
| Employees | 172 | KR#1,197/2,436 Sec#100/234 |
| Value | ||
| P/E | 5.38x | KR#336/2,436 Sec#11/234 |
| P/B | 0.45x | KR#718/2,436 Sec#23/234 |
| PEG | 0.11x | KR#403/2,436 Sec#23/234 |
| P/S | 0.59x | KR#1,063/2,436 Sec#48/234 |
| EV/EBITDA | 3.81x | KR#142/2,436 Sec#3/234 |
| FCF Yield | 34.03% | KR#168/2,436 Sec#2/234 |
| Profitability | ||
| ROE | 8.40% | KR#656/2,436 Sec#41/234 |
| ROA | 7.17% | KR#412/2,436 Sec#32/234 |
| Op. Margin | 11.61% | KR#409/2,436 Sec#36/234 |
| Revenue Growth | 1.92% | KR#1,318/2,436 Sec#122/234 |
| Earnings Growth | 49.88% | KR#566/2,436 Sec#32/234 |
| Financial Health | ||
| Debt Ratio | 17.12% | KR#35/2,436 Sec#7/234 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/234 |
| FCF | 12.65B KRW | KR#646/2,436 Sec#37/234 |
| Cash | 9.40B KRW | KR#1,704/2,436 Sec#138/234 |
| Current Ratio | 6.63x | KR#196/2,436 Sec#45/234 |
| Net Debt/EBITDA | -1.29x | KR#405/2,436 Sec#21/234 |
| Dividend | ||
| Div. Yield | 5.36% | KR#249/2,436 Sec#8/234 |
| Div. Growth | 12.50% | KR#529/2,436 Sec#29/234 |
| Performance | ||
| 1Y Return | -27.08% | KR#1,439/2,436 Sec#122/234 |
| 1M Return | 0.30% | KR#661/2,436 Sec#52/234 |
| From 52W High | -34.62% | KR#506/2,436 Sec#32/234 |
| 1Y MDD | -37.29% | KR#417/2,436 Sec#32/234 |
| Trading | ||
| Volume | 5,013 shares | KR#2,236/2,436 Sec#217/234 |
| Foreign Own. | 3.04% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 628 KRW | KR#834/2,436 Sec#62/234 |
| BPS | 7,604 KRW | KR#1,111/2,436 Sec#81/234 |
Company Info
Koryo Pharm, established in 1980, manufactures and sells pharmaceuticals, listing on the KOSDAQ market in 2000. The company produces and distributes over-the-counter drugs, including Haben, a leading cold medicine in Korea, along with professional pharmaceuticals for central nervous system diseases such as dementia and epilepsy. Committed to public health, it conducts research and development for new drugs and generics, with its R&D capabilities recognized through patent applications and technology certifications. Koryo Pharm is headquartered in Icheon, Gyeonggi-do.